Background The evidence on associations between ultra-processed foods (UPF) and lung cancer risk is limited and inconsistent.

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Altria's dividend growth and high yield are appealing, supported by stable operating cash flows over the past decade. Check ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive surprises than negative ones.

In April 2025, Radiopharm dosed the first patient in the U.S. Phase 2b imaging study of 18F-RAD101. The multicenter, open-label, single arm Phase 2b clinical trial is evaluating the diagnostic ...

When the patient opted against surveillance CT scans and a follow-up PET scan, her physician ordered the CyPath® Lung test in March 2025. The test result of 0.56 – classified as “likely malignancy” – ...

Background Heart auscultation is a widely used and cost-effective clinical tool for detecting valvular heart disease (VHD), ...

Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...